Sun Pharmaceutical Industries, India's largest drugmaker by revenue, is preparing a $12 billion binding offer to acquire Organon & Co., the women's health-focused pharmaceutical company spun off from Merck (MSD) in 2021. If completed, the deal would become the largest overseas acquisition by an Indian pharmaceutical company, surpassing all previous benchmarks and sending shockwaves through the global generics, API, and finished-dose manufacturing landscape.
According to reports citing sources familiar with the matter, Sun Pharma has completed more than three months of comprehensive due diligence on Organon and is now finalizing its financing package. Global banking institutions including JPMorgan and Mitsubishi UFJ are reportedly involved in structuring the transaction, while additional consortia comprising private equity and strategic investors remain in competitive discussions.
Organon, which carries approximately $8 billion in debt, would be acquired on an enterprise-value basis of roughly $20 billion. Sun Pharma, which holds approximately $3.2 billion in net cash, would need significant external financing to close the deal — a factor that has reportedly introduced some complexity, given recent global market volatility.
While Organon is best known as the world's only major pharmaceutical company primarily focused on women's health, its portfolio extends well beyond reproductive health. The company markets a diverse range of products including biosimilars, cardiovascular therapies, and dermatology products across global markets.
Notably, Organon's historical connection to one of pharma's most successful products adds an intriguing layer to the acquisition story. The company that would eventually become Organon originally developed the PD-1 antibody that became pembrolizumab — now marketed by Merck as Keytruda, the world's best-selling cancer drug. That molecule was part of Organon's pipeline when Schering-Plough acquired the company in 2007, and subsequently transferred to Merck through its 2009 acquisition of Schering-Plough.
For Sun Pharma, Organon's established commercial infrastructure in developed markets — particularly the US, Europe, and Japan — represents a strategic asset that would significantly accelerate the Indian company's transition from a generics-focused business to a diversified pharmaceutical enterprise.
Under founder and chairman Dilip Shanghvi, Sun Pharma has been methodically building its presence in branded and specialty pharmaceuticals. The company's 11 innovative drugs generated $1.21 billion in US sales last year, led by Ilumya (tildrakizumab) for plaque psoriasis, which alone contributed $681 million.
The Organon bid follows Sun Pharma's $416 million acquisition of Checkpoint Therapeutics in 2025, which gave the Indian company access to Unloxcyt, an anti-cancer agent. Each successive deal signals Sun Pharma's intent to build a balanced portfolio of generics, biosimilars, and branded innovative therapies.
Shanghvi has stated that the company needs to expand into innovative research while maintaining its strength in generics — and the Organon acquisition would represent the most aggressive execution of that vision to date.
A Sun Pharma–Organon combination would create a vertically integrated pharmaceutical powerhouse with significant implications for API sourcing and generics manufacturing:
Scale advantages in API procurement. Sun Pharma is already one of the world's largest API manufacturers, with production facilities across India, the US, and other markets. The addition of Organon's product portfolio would dramatically increase the company's API consumption volumes, potentially giving it greater negotiating power with intermediates and raw materials suppliers.
Generics portfolio consolidation. Organon's generics and biosimilars businesses, combined with Sun Pharma's existing portfolio, would create one of the broadest generics offerings in the global market. This consolidation could reshape competitive dynamics in key therapeutic areas, particularly in women's health and biosimilars.
Manufacturing network synergies. Sun Pharma's extensive global manufacturing network — spanning India, the US, Canada, Bangladesh, Hungary, and other markets — could be leveraged to optimize Organon's production costs and supply chain resilience. For CDMO partners and contract API suppliers, this could mean both opportunities (expanded volumes) and competitive pressure (vertical integration).
Biosimilar expansion. Organon has been building a biosimilar portfolio, and Sun Pharma's manufacturing capabilities in biologics could accelerate this strategy. This is particularly significant given the wave of biologic patent expirations expected through the end of the decade.
The Sun Pharma–Organon deal comes amid a broader surge in pharmaceutical M&A activity. In March 2026 alone, the industry saw multiple blockbuster transactions, including Gilead Sciences' $5 billion acquisition of ADC specialist Tubulis and several other billion-dollar deals. Market watchers are projecting that 2026 could be a record year for pharmaceutical mergers and acquisitions.
For Indian pharmaceutical companies specifically, the deal reflects a maturing of the sector. Indian pharma has historically been associated with low-cost generics manufacturing, but the country's largest players are increasingly competing for branded and innovative drug assets on the global stage. The Sun Pharma–Organon transaction, if it closes, would establish a new benchmark for Indian pharma's global ambitions.
Despite the strategic logic, several risk factors could complicate or derail the deal. Organon's substantial debt load raises questions about the financial engineering required to make the transaction work. Global market volatility has reportedly introduced uncertainty into the financing discussions, and Sun Pharma's stock price could face pressure if investors view the deal as too expensive or too leveraged.
Additionally, regulatory approval processes — particularly in the US, where both companies have significant operations — could introduce delays or conditions. Antitrust considerations may also arise in markets where the combined entity would hold dominant positions in specific generics categories.
For API suppliers, intermediates manufacturers, and CDMOs, the Sun Pharma–Organon deal represents both opportunity and disruption. On the opportunity side, the combined entity's expanded portfolio and manufacturing network could drive increased demand for high-quality intermediates and contract manufacturing services. On the disruption side, greater vertical integration could reduce the role of independent suppliers in certain product categories.
The key watch point is how Sun Pharma chooses to integrate Organon's supply chain. If the company pursues an aggressive vertical integration strategy — bringing more API and intermediates production in-house — independent suppliers could face competitive headwinds. If, however, Sun Pharma maintains a diversified supplier base, the combined scale could actually benefit the broader supply chain ecosystem.
One thing is certain: the global pharmaceutical supply chain is entering a period of significant restructuring, and the Sun Pharma–Organon deal is among the most consequential moves in that transformation.
